Status:
COMPLETED
Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study proposes to correlate the plasma dosage of VEN with the inhibition of its Bcl-2 target during the first treatment cycle. VEN will be measured sequentially during the first treatment cycle an...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Patient with acute myeloid leukemia (AML) not eligible for intensive chemotherapy
- Patients aged 18 or over
- Patient treated with the combination azacitidine (AZA) + venetoclax (VEN)
- Patient having signed the study informed consent form
- Patient with social security coverage
- Exclusion criteria :
- Patients receiving treatment inhibiting or inducing Cytochrome CYP3A4
- Presence of an active, uncontrolled infection
- Patient participating or having participated in a clinical drug trial in the month prior to inclusion.
- Vulnerable persons
Exclusion
Key Trial Info
Start Date :
February 26 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06030089
Start Date
February 26 2024
End Date
March 3 2025
Last Update
December 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital la Conception
Marseille, France
2
CHU de Nice
Nice, France